Greg Orshansky Selected Research

lipokinetix

4/2002

Severe hepatotoxicity associated with the dietary supplement LipoKinetix.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Greg Orshansky Research Topics

Disease

2	COVID-19 02/2022 - 01/2022
1	Asthma (Bronchial Asthma) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Respiratory Insufficiency (Respiratory Failure) 01/2022
1	Brain Edema (Cerebral Edema) 04/2002
1	Weight Loss (Weight Reduction) 04/2002
1	Acute Liver Failure (Fulminant Hepatic Failure) 04/2002

Drug/Important Bio-Agent (IBA)

2	Oxygen (Dioxygen)IBA 02/2022 - 01/2022
1	acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamide FDA Link 01/2022
1	AndrogensIBA 01/2022
1	lipokinetixIBA 04/2002

Therapy/Procedure

1	Cannula 02/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2022